Fundamental Analysis of LUCY SCIENTIFIC DISCOVERY IN(NASDAQ:LSDI) stock

Fundamental Rating

Taking everything into account, LSDI scores 2 out of 10 in our fundamental rating. LSDI was compared to 197 industry peers in the Pharmaceuticals industry. LSDI scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. LSDI does not seem to be growing, but still is valued expensively.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year LSDI has reported negative net income.

In the past year LSDI has reported a negative cash flow from operations.

1.2 Ratios

With a Return On Assets value of -263.81%, LSDI is not doing good in the industry: 93.85% of the companies in the same industry are doing better.

LSDI has a Return On Equity of -13934.86%. This is amonst the worse of the industry: LSDI underperforms 88.72% of its industry peers.

		Industry Rank	Sector Rank
ROA	-263.81%
ROE	-13934.86%
ROIC	N/A

ROA(3y)-104.73%

ROA(5y)N/A

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for LSDI so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

LSDI does not have a ROIC to compare to the WACC, probably because it is not profitable.

The number of shares outstanding for LSDI has been increased compared to 1 year ago.

The debt/assets ratio for LSDI has been reduced compared to a year ago.

2.2 Solvency

LSDI has an Altman-Z score of -21.53. This is a bad value and indicates that LSDI is not financially healthy and even has some risk of bankruptcy.

With a Altman-Z score value of -21.53, LSDI is not doing good in the industry: 87.18% of the companies in the same industry are doing better.

There is no outstanding debt for LSDI. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	-21.53

ROIC/WACCN/A

WACC7.62%

2.3 Liquidity

LSDI has a Current Ratio of 0.38. This is a bad value and indicates that LSDI is not financially healthy enough and could expect problems in meeting its short term obligations.

LSDI's Current ratio of 0.38 is on the low side compared to the rest of the industry. LSDI is outperformed by 95.90% of its industry peers.

LSDI has a Quick Ratio of 0.38. This is a bad value and indicates that LSDI is not financially healthy enough and could expect problems in meeting its short term obligations.

The Quick ratio of LSDI (0.38) is worse than 94.87% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	0.38
Quick Ratio	0.38

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

LSDI shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -97.22%.

EPS 1Y (TTM)-97.22%

EPS 3YN/A

EPS 5YN/A

EPS growth Q2Q-1544.44%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Revenue growth Q2QN/A

3.2 Future

Based on estimates for the next years, LSDI will show a very strong growth in Earnings Per Share. The EPS will grow by 23.49% on average per year.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next Y78.1%

EPS Next 2Y34.54%

EPS Next 3Y23.49%

EPS Next 5YN/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for LSDI. In the last year negative earnings were reported.

Also next year LSDI is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

LSDI's earnings are expected to grow with 23.49% in the coming years. This may justify a more expensive valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y34.54%

EPS Next 3Y23.49%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for LSDI!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

LUCY SCIENTIFIC DISCOVERY IN

NASDAQ:LSDI (5/20/2024, 11:42:50 AM)

1.16

-0.3 (-20.55%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryPharmaceuticals

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap2.04M

Analysts

Price Target

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-263.81%
ROE	-13934.86%
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	0.38
Quick Ratio	0.38
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

Growth

EPS 1Y (TTM)-97.22%

EPS 3YN/A

EPS 5Y

EPS growth Q2Q

EPS Next Y78.1%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5Y

Revenue growth Q2Q

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

LUCY SCIENTIFIC DISCOVERY IN (LSDI)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens